Journal of Vascular Nursing
Volume 28, Issue 2 , Pages 54-66 , June 2010

Definition of immobility in studies of thromboprophylaxis in hospitalized medical patients: A systematic review

A portion of this manuscript was previously presented as a poster at the American Society of Hematology Annual Meeting in 2007, and the abstract was published in Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 968.

References 

  1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):S381–S453
  2. Shojania KG, Duncan BW, McDonald KM, et al. Making health care safer: A critical analysis of patient safety practices. Evid Rep Technol Assess (Summ). 2001;43:i-668
  3. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83:14–19
  4. Leizorovicz A, Mismetti P. Preventing venous thromboembolism in medical patients. Circulation. 2004;110(24 suppl_IV):IV-13-IV-19
  5. Ageno W, Squizzato A, Ambrosini F, et al. Thrombosis prophylaxis in medical patients: A retrospective review of clinical practice patterns. Haematologica. 2002;87(7):746–750
  6. Chopard P, Dorffler-Melly J, Hess U, et al. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med. 2005;257(4):352–357
  7. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93(2):259–262
  8. Kahn SR, Panju A, Geerts W, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res. 2007;119:145–155
  9. Rahim SA, Panju A, Pai M, Ginsberg J. Venous thromboembolism prophylaxis in medical inpatients: A retrospective chart review. Thromb Res. 2003;111(4-5):215–219
  10. Rashid ST, Thursz MR, Razvi NA, et al. Venous thromboprophylaxis in UK medical inpatients. J R Soc Med. 2005;98(11):507–512
  11. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: Findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132(3):936–945
  12. Douketis JD, Lloyd NS. Why A-level evidence does not make it to clinicians' A-list: The case of thromboprophylaxis in medical patients. Evid Based Med. 2008;13(5):133–134
  13. Ageno W, Dentali F. Prevention of in-hospital VTE: Why can't we do better?. The Lancet. 2008;371(9610):361–362
  14. Michota FA. Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: The quality improvement process. J Gen Intern Med. 2007;22(12):1762–1770
  15. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. New Engl J Med. 2005;352(10):969–977
  16. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1109–1114
  17. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM Study. J Thromb Thrombolysis. 2006;22(1):31–38
  18. Bergmann JF, Caulin C. Heparin prophylaxis in bedridden patients. Lancet. 1996;348(9021):205–206
  19. Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J. 1981;26(2):115–117
  20. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate S, et al. Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology. 1988;39(6):505–513
  21. Ginsberg JS, Bates SM, Oczkowski W, et al. Low-dose warfarin in rehabilitating stroke survivors. Thromb Res. 2002;107(6):287–290
  22. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet. 1996;347(9012):1357–1361
  23. Lederle FA, Sacks JM, Fiore L, et al. The prophylaxis of medical patients for Thromboembolism Pilot Study. Am J Med. 2006;119(1):54–59
  24. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost. 1996;76(4):529–534
  25. Caulin C. The influence of CY 216 administration on hospital mortality of general in-patients: International collaborative double-blind study, methods and preliminary results. In:  Breddin K, FJSME  editor. Stuttgart: Shattauer; 1989;149–145
  26. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ. 2006;332:325–329
  27. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis. 1986;16(2):159–164
  28. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med. 1982;96(5):561–565
  29. Harenberg J, Kallenbach B, Martin U, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res. 1990;59(3):639–650
  30. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis. 1996;26(3):127–139
  31. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003;145(4):614–621
  32. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis. 1996;2(26 Suppl):49–56
  33. Leizorovicz A, Cohen A, Turpie A, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;100:874–879
  34. Luba M, Firek A, Kochanowski Z. Two models of thromboprophylaxis in acutely ill medical inpatients. Pol Arch Med Wewn. 2007;117(4):31–37
  35. Mahé I, Bergmann J, d'Azémar P, Vaissie JJ, Caulin C. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: A prospective randomised double-blind study. Eur J Clin Pharmacol. 2005;61(5):347–351
  36. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793–800
  37. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107:I9–16
  38. Kucher N, Spirk D, Kalka C, et al. Clinical predictors of prophylaxis use prior to the onset of acute venous thromboembolism in hospitalized patients. J Thromb Haemost. 2008;6:2082–2087
  39. Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm. 2007;64(1):69–76

PII: S1062-0303(09)00131-9

doi: 10.1016/j.jvn.2009.12.003

Journal of Vascular Nursing
Volume 28, Issue 2 , Pages 54-66 , June 2010

Article Tools